Dapiglutide
- 1 lab
- Human trial1
Outcomes
1Body weight
downin humans1−8.3%
1 study
Body weight
downin humans1−8.3%
Dapiglutide decreases body weight in humans (up to 8.3%).
“The placebo-adjusted reductions in body weight were up to a mean of 8.3% with dapiglutide after 13 weekly doses.”
Human trial13 weeks
Safety, Tolerability, and Clinical Effects of Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Agonist
ADA Scientific Sessions 2025 abstract13 Jun 2025
Latest
ADA Scientific Sessions 2025 Abstract
Safety, Tolerability, and Clinical Effects of Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Agonist
Randomised trial in 54 peopleInterventions